Neurothera Labs Company Profile - aVenture Research
Neurothera Labs
Neurothera Labs is a clinical-stage pharmaceutical company developing cannabinoid-based CNS treatments, including its SCI-110 platform pairing THC with CannAmide.
Neurothera Labs is a clinical-stage Israeli pharmaceutical company developing proprietary cannabinoid-based treatments for central nervous system disorders. It builds its formulations on CannAmide combined with different cannabinoids: CannAmide, also called TheraPEA, is based on palmitoylethanolamide, an endocannabinoid-like lipid messenger. Its SCI-110 platform pairs THC with CannAmide, and its SCI-210 platform pairs CBD with CannAmide.
Additional patent applications are pending in the United States, Europe, China, Japan and other jurisdictions. CannAmide holds a product licence from Health Canada's Natural and Non-prescription Health Products Directorate. Manufacturing processes for the active ingredient and the final dosage form meet GMP requirements.
SCI-110 is proprietary cannabinoid-based drug candidate combining dronabinol and palmitoylethanolamide in one oral form for Tourette syndrome and Alzheimer's disease.
